Seeking Alpha

Immunomedics (IMMU +3.3%) says its entered into an agreement with Algeta ASA (ALGZF.PK) for the...

Immunomedics (IMMU +3.3%) says its entered into an agreement with Algeta ASA (ALGZF.PK) for the development of a potential cancer treatment using IMMU's humanized anti-CD22 antibody, epratuzumab. Under the terms of the agreement, IMMU will provide clinical-grade antibody to Algeta, which has rights to evaluate epratuzumab for the treatment of cancer. Algeta will fund all preclinical and clinical development costs up to the end of Phase I testing.
Comments (1)
  • Home run well see
    28 Jan 2013, 04:02 PM Reply Like
DJIA (DIA) S&P 500 (SPY)